Senders Zachary J, Martin Robert C G
Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, KY 40202, USA.
Cancers (Basel). 2022 Mar 30;14(7):1754. doi: 10.3390/cancers14071754.
Several intratumoral immunotherapeutic agents have shown efficacy in controlling local disease; however, their ability to induce a durable systemic immune response is limited. Likewise, tumor ablation is well-established due to its role in local disease control but generally produces only a modest immunogenic effect. It has recently been recognized, however, that there is potential synergy between these two modalities and their distinct mechanisms of immune modulation. The aim of this review is to evaluate the existing data regarding multimodality therapy with intratumoral immunotherapy and tumor ablation. We discuss the rationale for this therapeutic approach, highlight novel combinations, and address the challenges to their clinical utility. There is substantial evidence that combination therapy with intratumoral immunotherapy and tumor ablation can potentiate durable systemic immune responses and should be further evaluated in the clinical setting.
几种瘤内免疫治疗药物已显示出在控制局部疾病方面的疗效；然而，它们诱导持久全身免疫反应的能力有限。同样，肿瘤消融因其在局部疾病控制中的作用而得到广泛认可，但通常仅产生适度的免疫原性效应。然而，最近人们认识到，这两种模式及其独特的免疫调节机制之间存在潜在的协同作用。本综述的目的是评估关于瘤内免疫治疗和肿瘤消融联合治疗的现有数据。我们讨论了这种治疗方法的基本原理，强调了新的联合方案，并探讨了其临床应用面临的挑战。有大量证据表明，瘤内免疫治疗和肿瘤消融联合治疗可增强持久的全身免疫反应，应在临床环境中进一步评估。
